Brokerages Set Indivior PLC (NASDAQ:INDV) Price Target at $39.33

Shares of Indivior PLC (NASDAQ:INDV) have earned an average recommendation of “Moderate Buy” from the seven analysts that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and six have issued a buy recommendation on the company. The average 12-month price objective among brokerages that have issued ratings on the stock in the last year is $39.3333.

INDV has been the subject of several analyst reports. HC Wainwright boosted their target price on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a research note on Monday, January 12th. Weiss Ratings raised shares of Indivior from a “hold (c)” rating to a “buy (b-)” rating in a research note on Monday, March 2nd. Zacks Research downgraded shares of Indivior from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 13th. Northland Securities set a $50.00 price objective on shares of Indivior in a research report on Tuesday, January 20th. Finally, Morgan Stanley reissued an “overweight” rating and set a $36.00 price objective on shares of Indivior in a research note on Wednesday, December 3rd.

Insider Buying and Selling

In other Indivior news, Director Mark Stejbach acquired 775 shares of the stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director directly owned 16,847 shares in the company, valued at approximately $596,215.33. This trade represents a 4.82% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Daniel A. Ninivaggi bought 775 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The stock was acquired at an average price of $35.39 per share, with a total value of $27,427.25. Following the completion of the purchase, the director directly owned 16,923 shares of the company’s stock, valued at approximately $598,904.97. The trade was a 4.80% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders acquired a total of 4,871 shares of company stock worth $172,385 in the last three months.

Institutional Trading of Indivior

A number of hedge funds have recently added to or reduced their stakes in INDV. CWM LLC purchased a new stake in Indivior in the 3rd quarter valued at about $25,000. Quarry LP purchased a new position in shares of Indivior during the 3rd quarter worth about $26,000. Raymond James Financial Inc. acquired a new stake in shares of Indivior in the second quarter worth approximately $26,000. Salomon & Ludwin LLC purchased a new stake in Indivior in the fourth quarter valued at approximately $30,000. Finally, Harbor Capital Advisors Inc. grew its holdings in Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock valued at $37,000 after purchasing an additional 781 shares during the period. 60.33% of the stock is owned by institutional investors and hedge funds.

Indivior Stock Performance

Indivior stock opened at $33.34 on Wednesday. Indivior has a fifty-two week low of $8.64 and a fifty-two week high of $38.00. The company has a market capitalization of $4.17 billion, a price-to-earnings ratio of 20.33 and a beta of 0.83. The stock has a fifty day moving average of $33.99 and a two-hundred day moving average of $30.51.

Indivior (NASDAQ:INDV) last issued its quarterly earnings data on Thursday, February 26th. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.17. The business had revenue of $358.00 million for the quarter, compared to the consensus estimate of $305.62 million. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%. On average, analysts forecast that Indivior will post 1.22 EPS for the current fiscal year.

Indivior Company Profile

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.